Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Conditions
Keywords
AML, ALL, MDS, Allogeneic transplant, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Adoptive cell therapy, Non-myeloablative
Brief summary
This is a new platform in non-myeloablative allogeneic stem cell transplantation to improve survival by harnessing the immunologic potential of donor T-cells to induce and maintain long-term remissions in patients with hematologic malignancies without undue toxicity. This study involves is the first study in humans directed at optimizing the graft vs leukemia effect by infusing activated T-cells from healthy donors prophylactically, months after recovery from the initial transplant. Investigators are studying whether the activation of donor cells prior to infusion will enhance the patient's ability to seek and destroy residual malignant cells while also helping the immune system to fight infection without increasing the immune reaction against the host.
Interventions
DRUGNon-myeloablative allogeneic stem cell transplant with prophylactic activated DLI
Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
DRUGProphylactic delayed ADLI
Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
DRUGProphylactic delayed activated donor lymphocyte infusion
Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
Sponsors
Abramson Cancer Center at Penn Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Patient-related Parameters: * Patients must have a healthy histocompatible donor (A, B and DR match); either sibling or unrelated volunteer identified through the NMDP * Age between 18 and 70 years old * Life expectancy greater than 3 months. * ECOG performance status 0-1. * Patients must have acceptable organ function: * total bilirubin \<2.0 * AST and ALT \< 3 x normal, unless increases are thought to be either from non-hepatic causes (i.e hemolysis) or related to underlying disease (such as liver involvement with leukemia); * creatinine \<2.0 or creatinine clearance \>40 ml/min (calculated or collected); * Cardiac: An ejection fraction \>40% on MUGA or echocardiogram; * Pulmonary: corrected DLCO \>50%
Exclusion criteria
Subjects: * Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study. Patients must have recovered from adverse events due to agents administered more than 4 weeks earlier. * Patients with uncontrolled or untreated central nervous system involvement * Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * HIV positive patients are excluded * Pregnant women * Patients who are breastfeeding Donors: * Sibling donors will be evaluated according to the standard practice of the University of Pennsylvania Bone Marrow and Stem Cell Transplant Program * Unrelated donor evaluations and consent will be performed by an NMDP donor center according to standard guidelines and procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the safety and feasibility of administering prophylactic donor lymphocyte infusion (DLI) after non-myeloablative transplant (NMT). | Six months after last patient entered on study. |
Countries
United States
Outcome results
None listed